According to the TCGA pan-cancer cohort, PBRM1 mutation frequency was 5%, with the most prevalent in ccRCC (29.9%), followed by uterine corpus endometrial carcinoma (UCEC) (13.8%) and SKCM (9.3%) (Figure 5B). Here, PBRM1 is linked to cancer.